Differential patterns of spinal cord pathology induced by MP4, MOG peptide 35-55, and PLP peptide 178-191 in C57BL/6 mice

APMIS

Volumn 119, Issue 6, 2011, Pages 336-346

  Kuerten, Stefanie ^a   Gruppe, Traugott L ^a   Laurentius, Laura Maria ^a   Kirch, Christiane ^a   Tary Lehmann, Magdalena ^b   Lehmann, Paul V ^b   Addicks, Klaus ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Axonopathy; C57BL 6; CNS; Demyelination; EAE; MS

Indexed keywords

HYBRID PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DEMYELINATION; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; MOTONEURON; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SPINAL CORD ATROPHY;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; MICE; MICE, INBRED C57BL; MOTOR NEURON DISEASE; MYELIN BASIC PROTEINS; MYELIN PROTEOLIPID PROTEIN; MYELIN-ASSOCIATED GLYCOPROTEIN; PEPTIDE FRAGMENTS; PHENOTYPE; RECOMBINANT FUSION PROTEINS; SPINAL CORD;

EID: 79955971449     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2011.02744.x     Document Type: Article

References (25)

1. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683-747.
2. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006;129:1953-71.
3. Lassmann H, Brück W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007;17:210-8.
4. Steinman L. The gray matter aspects of white matter disease in multiple sclerosis. Proc Natl Acad Sci USA 2009;106:8083-4.
5. Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 2009;65:239-48.
6. Goverman J, Brabb T. Rodent models of experimental allergic encephalomyelitis applied to the study of multiple sclerosis. Lab Anim Sci 1996;46:482-92.
7. Mix E, Meyer-Rienecker H, Zettl UK. Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations. J Neurol 2008;255(Suppl 6):7-14.
8. Krishnamoorthy G, Wekerle H. EAE: an immunologist's magic eye. Eur J Immunol 2009;39: 2031-5.
9. Bernard CC. Experimental autoimmune encephalomyelitis in mice - genetic control of susceptibility. J Immunogenet 1976;3:263-74.
10. Gasser DL, Goldner-Sauve A, Hickey WF. Genetic control of resistance to clinical EAE accompanied by histological symptoms. Immunogenetics 1990;31:377-82.
11. Mendel I, Kerlero de Rosbo N, Ben-Nun A. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells. Eur J Immunol 1995;25:1951-9.
12. Bernard CC, Johns TG, Slavin A, Ichikawa M, Ewing C, Liu J, et al. Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. J Mol Med 1997;75:77-88.
13. Oliver AR, Lyon GM, Ruddle NH. Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL/6 mice. J Immunol 2003;171:462-8.
14. Tompkins SM, Padialla J, Dal Canto MC, Ting JP, Van Kaer L, Miller SD. De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis. J Immunol 2002;168:4173-83.
15. Kuerten S, Lichtenegger FS, Faas S, Angelov DN, Tary-Lehmann M, Lehmann PV. MBP-PLP fusion protein-induced EAE in C57BL/6 mice. J Neuroimmunol 2006;178:4749-56.
16. Kuerten S, Javeri S, Tary-Lehmann M, Lehmann PV, Angelov DN. Fundamental differences in the dynamics of CNS lesion development and composition in MP4-, and MOG peptide 35-55-inuced experimental autoimmune encephalomyelitis. Clin Immunol 2008;129:256-67.
17. Zappia E, Cassaza S, Pedemonte FB, Bonanni I, Gerdoni E, Giunti D, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005;106:1755-61.
18. Kuerten S, Kostova-Bales DA, Frenzel LP, Tigno JT, Tary-Lehmann M, Angelov DN, et al. MP4-, and MOG:35-55-induced EAE in C57BL/6 mice differentially targets brain, spinal cord and cerebellum. J Neuroimmunol 2007;189:31-40.
19. Lassmann H, Ransohoff RM. The CD4-Th1 model for multiple sclerosis: a critical re-appraisal. Trends Immunol 2004;25:132-7.
20. Lucchinetti CF, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2001;47:707-17.
21. Bannerman PG, Hahn A, Ramirez S, Morley M, Bönnemann C, Yu S, et al. Motor neuron pathology in experimental autoimmune encephalomyelitis: studies in THY1-YFP transgenic mice. Brain 2005;128:1877-86.
22. Fisher E, Lee JC, Nakamura K, Rudick RA. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008;64:255-65.
23. Fisniku LK, Chard DT, Jackson JS, Anderson VM, Altmann DR, Miszkiel KA, et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008;64:247-54.
24. Derfuss T, Parikh H, Velhin S, Braun M, Mathey E, Krumbholz M, et al. Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc Natl Acad Sci USA 2009;106:8302-7.
25. Rudick RA, Trapp BD. Gray-matter injury in multiple sclerosis. N Engl J Med 2009;361:1505-6.